

## Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.

**March 6, 2025**

Company announcement no. 09

<b>1.</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Anders Lund	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Chief Operating Officer	
b)	Initial notification/ Amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Novozymes A/S	
b)	LEI	529900T6WNZXD2R3JW38	
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	B-Shares	
	Identification code	DK0060336014	
b)	Nature of the transaction	Exercise of stock options (purchase)	
c)	Price(s) and volume(s)	<b>Price(s)</b>	<b>Volume(s)</b>
		DKK 249.4	26,550 shares
		DKK 301.0	24,711 shares
		DKK 274.9	32,699 shares
d)	Aggregated information	Number of shares: 83,960	
	- Aggregated volume	Average price, DKK: 274.52	
	- Price	Transaction value, DKK: 23,048,536.10	
e)	Date of transaction	March 5, 2025	
f)	Place of the transaction	Outside a trading venue	

### Contact information

Investor relations

Tobias Bjorklund  
+45 3077 8682

[tobb@novonesis.com](mailto:tobb@novonesis.com)

Anders Enevoldsen  
+45 5350 1453

[adev@novonesis.com](mailto:adev@novonesis.com)

Katrine Spedtsberg Poulsen  
[kats@novonesis.com](mailto:kats@novonesis.com)

### About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

### Novozymes A/S, part of

### Novonesis Group

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

<b>1.</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Anders Lund
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, Chief Operating Officer
b)	Initial notification/ Amendment	Initial notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Novozymes A/S
b)	LEI	529900T6WNZXD2R3JW38
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument  Identification code	B-Shares  DK0060336014
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)	See Appendix
d)	Aggregated information - Aggregated volume - Price	Number of shares: 83,960 Average price, DKK: 441.30 Transaction value, DKK: 37,051,545.73
e)	Date of transaction	March 5, 2025
f)	Place of the transaction	See Appendix

## Appendix

### MARKET ORDER RESPONSES

Hide 

Response type	Date	Trading location	Quantity	Executed price
Partial fill	Mar 5, 2025	Off Exchange	83,869 shares	DKK 441.30
Partial fill	Mar 5, 2025	CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING	57 shares	DKK 441.20
Fill	Mar 5, 2025	Off Exchange	34 shares	DKK 441.40